BeyondSpring (BYSI) Total Liabilities (2015 - 2026)
BeyondSpring (BYSI) posted Total Liabilities of $48.8 million for Q1 2026, down 2.33% sequentially from $49.9 million in Q4 2025, and down 2.03% YoY from $49.8 million in Q1 2025.
BeyondSpring (BYSI) Total Liabilities (2015 - 2026) Analysis & Trends
BeyondSpring has reported Total Liabilities for 12 years, with the latest figure at $48.8 million in Q1 2026.
- Quarterly Total Liabilities fell 2.03% year-over-year to $48.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.8 million (down 2.03% YoY) and the FY2025 annual result came in at $49.9 million, up 2.72% from the prior year.
- Total Liabilities fell to $48.8 million in Q1 2026 per BYSI's latest filing, from $49.9 million in the prior quarter.
- Over five years, Total Liabilities peaked at $52.0 million in Q2 2022 and troughed at $47.2 million in Q2 2024.
- A 5-year average of $49.0 million and a median of $48.8 million in 2026 frame the typical range for Total Liabilities.
- The widest YoY moves for Total Liabilities: up 110.32% in 2022, down 10.93% in 2022.
- Over 5 years, Total Liabilities stood at $49.2 million in 2022, then fell by 1.95% to $48.3 million in 2023, then climbed by 0.69% to $48.6 million in 2024, then advanced by 2.72% to $49.9 million in 2025, then decreased by 2.33% to $48.8 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $48.8 million, $49.9 million, and $49.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | BeyondSpring | 30.22 Mn | 30.22 Mn | - | 50.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.63 Mn |
| Mar 31, 2026 | 48.76 Mn |
| Dec 31, 2025 | 49.92 Mn |
| Sep 30, 2025 | 49.29 Mn |
| Jun 30, 2025 | 48.59 Mn |
| Mar 31, 2025 | 49.77 Mn |
| Dec 31, 2024 | 48.60 Mn |
| Jun 30, 2024 | 47.17 Mn |
| Dec 31, 2023 | 48.27 Mn |
| Jun 30, 2023 | 47.57 Mn |
| Dec 31, 2022 | 49.23 Mn |
| Jun 30, 2022 | 52.03 Mn |
| Dec 31, 2021 | 55.27 Mn |
| Sep 30, 2021 | 59.21 Mn |
| Jun 30, 2021 | 24.74 Mn |
| Mar 31, 2021 | 21.53 Mn |
| Dec 31, 2020 | 25.22 Mn |
| Sep 30, 2020 | 16.47 Mn |
| Jun 30, 2020 | 15.10 Mn |
| Mar 31, 2020 | 15.51 Mn |